Nothing Special   »   [go: up one dir, main page]

UA111305C2 - Конденсовані лактами арилу та гетероарилу - Google Patents

Конденсовані лактами арилу та гетероарилу

Info

Publication number
UA111305C2
UA111305C2 UAA201505087A UAA201505087A UA111305C2 UA 111305 C2 UA111305 C2 UA 111305C2 UA A201505087 A UAA201505087 A UA A201505087A UA A201505087 A UAA201505087 A UA A201505087A UA 111305 C2 UA111305 C2 UA 111305C2
Authority
UA
Ukraine
Prior art keywords
lactams
heteroaryl
condensed
aryl
compounds
Prior art date
Application number
UAA201505087A
Other languages
English (en)
Inventor
Мартін Пол Едвардс
Роберт Арнолд Кампф
Бей-Бей Кун
Індраван Джеймс МакЕлпайн
Саша Нінковіч
Юджин Юаньцзінь Руй
Скотт Ченнінґ Саттон
Джон Говард Тетлок
Мартін Джеймс Вайтс
Люк Реймонд Зендер
Original Assignee
Пфайзер Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Інк. filed Critical Пфайзер Інк.
Publication of UA111305C2 publication Critical patent/UA111305C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Винахід стосується сполук загальної формули (І), (I)в якій R, R, U, V, L, М, R, m, Χ, Υ та Ζ є такими, як тут визначено, та їх фармацевтично прийнятних солей, фармацевтичних композицій, які містять такі сполуки та солі, та способів застосування таких сполук, солей та композицій для лікування аномального клітинного розвитку, включаючи рак.
UAA201505087A 2012-12-21 2013-05-12 Конденсовані лактами арилу та гетероарилу UA111305C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261740596P 2012-12-21 2012-12-21
PCT/IB2013/060682 WO2014097041A1 (en) 2012-12-21 2013-12-05 Aryl and heteroaryl fused lactams

Publications (1)

Publication Number Publication Date
UA111305C2 true UA111305C2 (uk) 2016-04-11

Family

ID=49917684

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201505087A UA111305C2 (uk) 2012-12-21 2013-05-12 Конденсовані лактами арилу та гетероарилу

Country Status (47)

Country Link
US (3) US9040515B2 (uk)
EP (2) EP3339303B9 (uk)
JP (1) JP5909308B2 (uk)
KR (1) KR101712441B1 (uk)
CN (1) CN104870435B (uk)
AP (1) AP2015008574A0 (uk)
AR (1) AR094174A1 (uk)
AU (1) AU2013365908C1 (uk)
BR (1) BR112015014678B1 (uk)
CA (1) CA2893339C (uk)
CL (1) CL2015001733A1 (uk)
CR (2) CR20200273A (uk)
CU (1) CU24414B1 (uk)
CY (2) CY1119883T1 (uk)
DK (2) DK2935238T3 (uk)
DO (1) DOP2015000157A (uk)
EA (1) EA028317B1 (uk)
EC (1) ECSP15031579A (uk)
ES (2) ES2658974T3 (uk)
GE (1) GEP201706718B (uk)
GT (1) GT201500190A (uk)
HK (1) HK1208866A1 (uk)
HR (2) HRP20180060T1 (uk)
HU (2) HUE050009T2 (uk)
IL (1) IL239520B (uk)
LT (2) LT3339303T (uk)
MA (1) MA38175B1 (uk)
MD (1) MD4664C9 (uk)
ME (2) ME03793B (uk)
MX (2) MX2015008058A (uk)
MY (2) MY192259A (uk)
NO (1) NO2961649T3 (uk)
NZ (1) NZ708801A (uk)
PE (1) PE20151090A1 (uk)
PH (1) PH12015501367B1 (uk)
PL (2) PL3339303T3 (uk)
PT (2) PT2935238T (uk)
RS (2) RS60582B9 (uk)
SG (1) SG11201504076XA (uk)
SI (2) SI2935238T1 (uk)
TN (1) TN2015000281A1 (uk)
TR (1) TR201802791T4 (uk)
TW (1) TWI546293B (uk)
UA (1) UA111305C2 (uk)
UY (2) UY38712A (uk)
WO (1) WO2014097041A1 (uk)
ZA (1) ZA201504437B (uk)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2780013A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2812001B1 (en) 2012-02-10 2017-06-14 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
LT2935303T (lt) 2012-12-21 2021-03-25 Janssen Biopharma, Inc. 4'-fluor-nukleozidai, 4'-fluor-nukleotidai ir jų analogai, skirti hcv gydymui
UA111305C2 (uk) * 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
EA031892B1 (ru) * 2014-06-17 2019-03-29 Пфайзер Инк. Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2
WO2015193768A1 (en) * 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
CA2965729A1 (en) * 2014-10-28 2016-05-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ｅｚｈ２抑制劑
US20180271857A1 (en) 2014-12-23 2018-09-27 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
EP3274343B1 (en) * 2015-03-27 2020-03-04 Syngenta Participations AG Microbiocidal heterobicyclic derivatives
TW201708210A (zh) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Ｚｅｓｔｅ同源物２增強子之抑制劑
TW201718598A (zh) * 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
KR20180081587A (ko) 2015-11-19 2018-07-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤조푸란 유도체, 이의 제조 방법 및 의학에서의 이의 용도
WO2017191545A1 (en) * 2016-05-05 2017-11-09 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018086589A1 (zh) * 2016-11-11 2018-05-17 上海海雁医药科技有限公司 1,5,7-三取代的异喹啉衍生物、其制法与医药上的用途
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
JP7257328B2 (ja) 2017-05-18 2023-04-13 ジエンス ヘンルイ メデイシンカンパニー リミテッド ベンゾフラン誘導体遊離塩基の結晶およびその製造方法
KR102635949B1 (ko) 2017-05-18 2024-02-14 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 종양 치료용 약물의 제조에 있어서의 ezh2 억제제 및 btk 억제제의 조합물의 용도
CN106977483A (zh) * 2017-06-02 2017-07-25 遵义医学院 一种二氟烷基取代的黄酮醇、异黄酮醇和香豆素类化合物的合成方法
KR20200088386A (ko) 2017-11-14 2020-07-22 화이자 인코포레이티드 Ezh2 억제제 병용 요법
KR102451529B1 (ko) 2018-01-31 2022-10-06 미라티 테라퓨틱스, 인크. Prc2 억제제
CA3102777A1 (en) * 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
CN112399857A (zh) 2018-07-09 2021-02-23 盲人庇护基金会 Prc2亚单位的抑制治疗眼失调
US11999716B2 (en) * 2018-10-24 2024-06-04 Vanderbilt University WDR5 inhibitors and modulators
CN111320582A (zh) * 2018-12-17 2020-06-23 江苏恩华药业股份有限公司 一种类酰胺类衍生物及其中间体的制备方法
KR102689665B1 (ko) * 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
KR102386403B1 (ko) * 2020-08-13 2022-04-15 한미약품 주식회사 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
IL300577A (en) * 2020-08-13 2023-04-01 Hanmi Pharmaceutical Co Ltd New derivatives of dioxoloisoquinolinone and their use
CN116457348A (zh) * 2021-02-26 2023-07-18 南京药石科技股份有限公司 新型ezh2抑制剂及其用途
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846412A (en) 1971-03-18 1974-11-05 Lepetit Spa Dihydro-2-amino-isoquinolines and their derivatives
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JP2009504759A (ja) 2005-08-16 2009-02-05 メモリ ファーマセチカル コーポレーション ホスホジエステラーゼ１０阻害剤
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US20110251216A1 (en) 2010-02-19 2011-10-13 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
EP2566479B1 (en) 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
US8536179B2 (en) 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
EP2566328B1 (en) 2010-05-07 2015-03-04 GlaxoSmithKline LLC Indazoles
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤、およびその使用方法
JP2013537210A (ja) 2010-09-16 2013-09-30 ノバルティス アーゲー １７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
ES2951688T3 (es) * 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
TWI598336B (zh) * 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9730925B2 (en) 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6254169B2 (ja) 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
CA2895156A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
ES2664985T3 (es) 2012-12-21 2018-04-24 Plexxikon Inc. Compuestos y métodos para modulación de quinasa, e indicaciones de los mismos
LT2935303T (lt) 2012-12-21 2021-03-25 Janssen Biopharma, Inc. 4'-fluor-nukleozidai, 4'-fluor-nukleotidai ir jų analogai, skirti hcv gydymui
FR3000065A1 (fr) 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
EA037633B1 (ru) 2012-12-21 2021-04-23 Джилид Сайэнс, Инк. Полициклические карбамоилпиридоновые соединения, их фармацевтические композиции и применение
FR3000059A1 (fr) 2012-12-21 2014-06-27 Saint Gobain Placo Composition pour plaques de platre et produits obtenus
CN104870466B (zh) 2012-12-21 2018-05-18 霍夫曼-拉罗奇有限公司 作为催产素激动剂的肽
PT2935222T (pt) 2012-12-21 2018-12-10 Epizyme Inc Inibidores de prmt5 e seus usos
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
EA031892B1 (ru) 2014-06-17 2019-03-29 Пфайзер Инк. Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2

Also Published As

Publication number Publication date
HRP20180060T1 (hr) 2018-02-23
CU20150062A7 (es) 2015-11-27
BR112015014678A2 (pt) 2017-07-11
HRP20201194T2 (hr) 2021-09-17
CA2893339C (en) 2017-06-13
PH12015501367A1 (en) 2015-09-02
MY192259A (en) 2022-08-12
NZ708801A (en) 2018-08-31
PL2935238T3 (pl) 2018-05-30
EP2935238A1 (en) 2015-10-28
PL3339303T3 (pl) 2021-01-25
AP2015008574A0 (en) 2015-07-31
ES2808987T9 (es) 2021-11-29
CA2893339A1 (en) 2014-06-26
US20150175572A1 (en) 2015-06-25
LT3339303T (lt) 2020-09-10
HUE038238T2 (hu) 2018-10-29
CN104870435B (zh) 2016-12-07
MX2020002924A (es) 2020-07-22
PT3339303T (pt) 2020-07-30
PT2935238T (pt) 2018-02-09
SG11201504076XA (en) 2015-06-29
ME03793B (me) 2021-04-20
KR20150100823A (ko) 2015-09-02
BR112015014678B1 (pt) 2021-12-07
TN2015000281A1 (fr) 2016-10-03
JP2016507497A (ja) 2016-03-10
WO2014097041A1 (en) 2014-06-26
CL2015001733A1 (es) 2015-10-23
IL239520B (en) 2018-05-31
DK3339303T3 (da) 2020-08-10
UY35225A (es) 2014-07-31
SI2935238T1 (en) 2018-04-30
SI3339303T1 (sl) 2020-09-30
CY1123237T1 (el) 2021-10-29
MD4664C9 (ro) 2020-07-31
PE20151090A1 (es) 2015-08-07
US20170233368A1 (en) 2017-08-17
AR094174A1 (es) 2015-07-15
US10246433B2 (en) 2019-04-02
MA38175B1 (fr) 2018-11-30
AU2013365908A1 (en) 2015-06-11
RS60582B9 (sr) 2021-09-30
DK2935238T3 (en) 2018-01-22
EA201590879A1 (ru) 2015-12-30
HUE050009T2 (hu) 2020-11-30
AU2013365908C1 (en) 2018-01-25
TR201802791T4 (tr) 2018-03-21
ZA201504437B (en) 2016-07-27
MD20150052A2 (ro) 2015-12-31
UY38712A (es) 2020-06-30
RS56815B1 (sr) 2018-04-30
IL239520A0 (en) 2015-08-31
LT2935238T (lt) 2018-02-26
MX2015008058A (es) 2015-10-30
EP3339303B1 (en) 2020-06-24
TW201446753A (zh) 2014-12-16
US9040515B2 (en) 2015-05-26
EA028317B1 (ru) 2017-11-30
KR101712441B1 (ko) 2017-03-07
GEP201706718B (en) 2017-08-10
CN104870435A (zh) 2015-08-26
ME02980B (me) 2018-10-20
CR20150279A (es) 2015-09-03
PH12015501367B1 (en) 2015-09-02
EP3339303B9 (en) 2021-07-21
CR20200273A (es) 2020-09-23
HRP20201194T1 (hr) 2020-11-13
GT201500190A (es) 2016-01-21
ES2808987T3 (es) 2021-03-02
JP5909308B2 (ja) 2016-04-26
US20140179667A1 (en) 2014-06-26
CY1119883T1 (el) 2018-06-27
HK1208866A1 (en) 2016-03-18
MD4664B1 (ro) 2019-12-31
RS60582B1 (sr) 2020-08-31
ECSP15031579A (es) 2017-08-31
DOP2015000157A (es) 2015-11-30
TWI546293B (zh) 2016-08-21
EP2935238B1 (en) 2017-12-27
NO2961649T3 (uk) 2018-02-17
ES2658974T3 (es) 2018-03-13
EP3339303A1 (en) 2018-06-27
MA38175A1 (fr) 2018-08-31
AU2013365908B2 (en) 2017-07-20
CU24414B1 (es) 2019-05-03
MY176307A (en) 2020-07-28

Similar Documents

Publication Publication Date Title
UA111305C2 (uk) Конденсовані лактами арилу та гетероарилу
PH12020550552A1 (en) Inhibitors of hepatitis c virus
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201490724A1 (ru) Замещенные соединения тетрагидроизохинолина в качестве ингибиторов фактора xia
MY177344A (en) Compounds and their methods of use
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201591024A1 (ru) Димерные соединения
EA201590787A1 (ru) Замещенные пиридопиразины в качестве ингибиторов syk
EA201590339A1 (ru) Новые антибактериальные соединения
EA201600394A1 (ru) Трициклические соединения пиперидина
EA201650003A1 (ru) Соединённые циклоалкилом дигетероциклические производные
EA201590331A1 (ru) Новые антибактериальные соединения
EA201600166A1 (ru) Производные пиперидина и азепина как модуляторы рецептора прокинетицина